

ALKERMES INC  
Form 8-K  
December 03, 2009

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): December 3, 2009  
ALKERMES, INC.  
(Exact Name of Registrant as Specified in its Charter)**

**PENNSYLVANIA**  
(State or Other Jurisdiction of  
Incorporation)

**1-14131**  
(Commission  
File Number)

**23-2472830**  
(I.R.S. Employer  
Identification No.)

**88 Sidney Street**  
**Cambridge, Massachusetts**  
(Address of principal executive offices)

**02139**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 494-0171**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On December 3, 2009, Alkermes, Inc. ( Alkermes ) entered into an agreement with Acceleron Pharma, Inc. ( Acceleron ) to license a proprietary long-acting Fc fusion technology platform, as described in the attached press release. On execution of the agreement, Alkermes made an upfront payment of \$2 million and an equity investment in Acceleron of \$8 million. Alkermes will record the \$2 million upfront payment as a research and development expense during the quarter ended December 31, 2009 and will record the \$8 million as an investment on the balance sheet. Richard Pops, the Chairman, President and Chief Executive Officer of Alkermes, is also a Director of Acceleron.

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

**Exhibit**

**No.**

**Description**

99.1 Press Release dated December 3, 2009

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALKERMES, INC.**

Date: December 3, 2009

By: /s/ James M. Frates  
James M. Frates  
Senior Vice President, Chief Financial  
Officer and Treasurer  
(Principal Financial and Accounting  
Officer)

---

**EXHIBIT INDEX**

**Exhibit**

**No.**

**Description**

99.1 Press Release dated December 3, 2009